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A murine model of chronic graft-versus-host disease 
(GVHD) was induced across minor histocompatibility 
barriers. This was done by injecting B10.D2 (H-2d) 
spleen cells into irradiated BALB/c (H-2d) mice. Chronic 
GVHD in this model includes features common to human 
idiopathic scleroderma, such as dermal fibrosis, loss of 
dermal fat a nd appendages, and a mononuclear cell fil -
trate. Serial skin biopsies showed a progressive loss of 
stainable mast cells in GVHD but not in irradiated con-
trols. Mast cell depletion was noted as well in the tongue 
and kidney capsule of GVHD mice. Mast cell depletion 
was noted as early as 11 days after GVHD induction and 
persisted for at least 56 days. A hypothesis is put forth 
linking the T -cell activation of GVHD, mast cell degran-
ulation, and increased fibrosis. The pertinence of this 
hypothesis to idiopathic scleroderma is pointed out. 
Graft-versus-host disease (GVHD) comprises a complex se-
ries of reactions which follow t he transplantation of histoin -
compatible immunocompetent T lymphocytes into immuno-
comprom ised hosts or hosts genetically unable to reject the 
donor cell s [1] . Donor cells and/or host cells may proliferate, 
leading to t he development of cytotoxic lymphocytes [2], im-
mu noincompetence [3], suppressor cells (4], and other disorders 
of imm une regu lation [5]. In t he chronic variety of GVHD, a 
number of changes occur, including t he development of autoim-
mune-like phenomena. Among t he most interesting is a syn-
drome resembling idiopathic scleroderma (progressive systemic 
sclerosis). This syndrome, seen in chronic GVHD in animals 
[6- 8] and huma ns [9,10), includes changes in the skin such as 
progressive fibrosis. It is particu larly noteworthy that t he 
chronic GVHD syndrome can occur when graft a nd donor a re 
matched at t he major histocompatibility complex (MHC) but 
differ only at minor ant igen loci. This is the situation in huma n 
bone marrow tra nsp lantation situations in which the donor 
and host are "HLA-ident ica l" but yet GVHD results [11] . In 
studyi ng a mouse model of chron ic GVHD, we found t hat mast 
cells as sta ined by toluidine blue were depleted from the skin 
and other organs. This change occurred only in mice with 
GVHD and not in con trol mice, and t herefore mast cell deple-
tion was not an effect of host irradiation. Cutaneous mast cell 
depletion in chron ic murine GVHD was independently noted 
in passing by Charley et al [12] but it was not quantitated, nor 
was its systemic nature discovered. We believe t hat t his mast 
cell depletion may be t he resul t of generalized immunosuppres-
sion and may be related to collagen deposition. 
We have exp lored a mouse model of chro nic GVHD using 
B10.D2 donors and BALB/c recipients. These strains of mice 
are MHC-ident ical (H-2d) and mls-identical (mlsh) and t heir 
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cells do not give a mixed leukocyte reaction [13]. Yet t hey 
differ at minor histocompatibility ant igens, and irradiated 
BALB/c mice given lymphoid cells from B10.D2 donors develop 
chronic GVHD. This syndrome includes weight loss, dermal 
fibrosis, loss of dermal fat , a mononuclear cell infiltrate in the 
skin, and loss of dermal appendages [13]. These changes a re 
similar to those seen in human idiopathic scleroderma. Ot hers 
have shown that chronic GVHD is accompanied by t he appear-
ance ofia+ keratinocytes [14,15]. We stained the skin and other 
organs at various times during the chronic GVHD process, 
using toluidine blue which has affi nity for mast cell granules. 
MATERIALS AND METHODS 
8AL8/c mice were obtained from Cumberland Laboratories and 
810.D2 mice from J ackson Laboratories. Female mice, aged 8- 12 weeks 
were used. To induce GVHD, 8AL8/c mice received 600- 1000 rads 
60Co and wi thin 2 h, 5- 10 x 107 810.D2 lymphoid cells. Control groups 
received 8ALB/c lymphoid cells. Some recipient groups were not 
irradiated. Groups contained 3 mice. 
Tissue Preparation and Mast Cell Counting 
Skin mast cells were identified in 5-l'm form alin -fi xed sections 
stained with 1% toluidine blue, pH 3.2. For each data point, the mast 
cells in 10 high-power fi elds (10 X 40) from 3 sections of each coded 
skin biopsy were counted by one observer, and averaged. (Results by 
another observer differed by less than 10%.) Standard deviations were 
similar to those in Table I. Sections of tongue were t rea ted and scored 
similarly. Kidney capsules (a rich source of mast cells [16]) were 
removed from sacrificed mice, placed on microscope slides, fixed in 
absolute ethanol, and stained with toluidine blue as above. Because 
capsule tissue stretches or contracts, quantitative measurements per 
square unit are not possible. Instead, coded samples were assigned 
semiquantitative scores representing mast cell densities. For skin and 
tongue, statistical comparisons were made with respective control 
groups:* (.05 > p > .01); ** (.01 > p > .001). 
RESULTS 
The data in Fig 1 show mast cell densit ies from sk in , tongue, 
and kidney capsule in groups of mice sacrificed 20, 42, 49, and 
56 days after induction of GVHD. By day 20, GVHD mice 
already had significantly fewer dermal mast cells than control 
mice (p < .05) and at days 42, 49, and 56, mast cell s were 
virt ually absent from the skin of such mice. Control BALB/c 
mice given 900 rads and BALB cells did show a slight loss of 
dermal mast cells which was probably a late effect of irradiation , 
as it was not present on day 49 if the recipients had received 0 
rads. The depletion of skin mast cells in t he B10.D2 ----7 BALB/ 
c combination required recipient irradiation s ince, on day 49, 
mast cell densit ies were normal in unirradiated BALB/c recip -
ients of B10.D2 cells . Indeed, without irradiation , GVHD does 
not occur in this model [13]. On day 56, tongue mast cells were 
depleted in GVHD recipients compared to syngeneic controls 
(p < .01). Mast cells in the kidney capsule were also lower in 
GVHD than in control mice at days 49 and 56. Intestinal mast 
cells, believed to be regulated differently from serosal and 
connective tissue mast cells [17] were not evaluated, as they 
are far less numerous in mice not infected wit h parasites [18]. 
To study the kinetics of mast cell depletion early in GVHD, 
BALB/c mice were given B10.D2 spleen cells and 600, 800, or 
1000 rads 6°Co (Table I). Serial skin biopsies were taken at 4, 
7, 11, and 14 days and stained for mast cells. Control BALB/c 
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Skin mast cells/high-power fie ld (± SO) 
Day 4 Day 7 Day 11 Day 14 
4.0 ± 0.28 5.2 ± 0.22 4.3 ± 0.55 3.3 ± 0.29* 
4.2 ± 1.50 5.4 ± 1.70 4.4 ± 0.29 2.3 ± 1.10* 
3.6 ± 0.66 5.3 ± 0.65 2.6 ± 1.30* 1.1 ± 0.74** 
4.7 ± 0.91 6.7 ± 1.50 6.1 ± 0.60 5.5 ± 1.10 
In the GVHD groups (A- C), BALB/c mice were irradiated and received 108 B10.D2 lymphoid cells (95% spleen, 5% lymph node) i.v. Control 
mice (D) received equal numbers of syngeneic cell s after irradiation. Serial skin biopsies were taken. Mast cells were quantitated as in Fig 1, and 
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FIG 1. Mast cell densities in the skin and other organs. On day 0, 
GV HO BALB/c recipients received 900 rads or 0 rads 60Co and were 
infused i v with 5 x 107 B10.02 spleen cells (e). Control BALB/c rec ipient~ ~eceived 900 rads or 0 rads 60Co and 5 . X 107 syngeneic 
BALB/c spleen cells (0). Groups of 3 mice were sacnficed on days 20, 
42, 49, and 56 (900 rads) and on day 49 (0 rads). 
mice received BALB/c cells and the highest dose of irradiation 
( 1000 rads). The results show t hat stainable mast cells were 
normal on day 4, but became less frequent in t he GVHD gro~ps 
(A-C) with t he most rapid disappearance in t he group w1th 
t he hi~hest dose of irradiat ion (group C). This depletion was 
not caused by irrad iation alone, as shown by t he controls (gr~up 
D), but is probably due to the greater seve ri ty of GVHD wh1ch 
is associated with higher doses of recipient irradiation [19). 
DISCUSSION 
The results presented above show t hat the development of 
t he chronic GVHD syndrome ac ross at least some minor his-
tocompatibili ty barriers in mice includes a progressive s~stem ic 
disappearance of sta inab le mast cells. Such a change 111 mast 
cells was not, however, seen in a different model of GVHD 
across a major histocompat ibility barrier using beige mice and 
unirradiated recipients [20). The differences between t hose 
resul ts and t hese experiments rema in to be explored. The 
nature of t he mast ce ll loss seen here is as yet uncertain. Mast 
cells are usually quantitated by counti ng cells. containing dis-
t inctive gra nules which are differentially stained with certa in 
dyes, such as toluidine blue [21 ). Reliable quanti tative methods 
to identify mast ce lls in t issues by means of surface markers, 
such as IgE or IgE receptors, are not yet avai lable. Skin hista-
mine will give no more information t han enumeration of tolui -
dine blue-stained cell s [16). The fa ilure to lind stainable mast 
cells might mean (a) t hat t he cells are dead, (b) t hat t hey have 
emigrated from t he skin , or (c) that they are chronically de-
granulated and not iden tifiable with histochemical stains. We 
favor t he latter explanation because preliminary ult rastructural 
studies do not show mast cells in the process of dying or being 
attacked by infiltrating cells, but instead show mast cells with 
very few granules but with considerable evidence of cell acti-
vation (AE Vatter, HN Cla man, manuscript in preparation). 
Furt hermore, other experiments indicate t hat at later times in 
chronic GVHD, (e.g., day 104) stainable dermal mast cells have 
returned to normal, consistent with recovery of the granulation 
and storage processes (HN Claman, RAF Clark, AE Vatter, C 
Huff, manuscript in preparation). The inability to find stain-
able mast cells has a parallel in the Joss of Ia+ Langerhans cells 
in t he skin during experimental GVHD [22) although it is not 
known whether the latter phenomenon occurred in organs other 
than the skin. 
A recent study by Janin-Mercier eta! noted that mast cells 
appeared to be increased in chronic human GVHD [23], a l-
t hough quantitation was not carried out. At first, t his finding 
may seem to contradict t he present report, but if depletion of 
mast cells in t he mouse model reflects mast cell activation, 
t hen both reports actually suggest increased mast cell fu.nction. 
The systemic involvment of mast ce lls in chronic GVHD 
may provide a link between several diverse phenomena, namely, 
T -cell activation , immunosuppression, and fibrosis . Activated 
T cells, such as t hose fo und in GVHD, can stimulate mast cells 
via soluble products promoting histamine synt hesis [24], his-
tamine release [25], and perhaps mast cell growth [26 ). In turn, 
mast cell degranu lation and histamine release activate sup-
pressor T cells bearing H-2 receptors [27], which would lead to 
systemic immunosuppression. Interactions between mast cells 
and fibroblasts are now being recognized [28,29], confirming 
t he well-established phenomenon of the appearance and prob-
able degranulat ion of mast cell s in fibrotic situations in t he 
skin [30], and in pulmonary fibrosis, both idiopathic [31] and 
radiation-induced [32). 
It is most provocative to relate the increased fibrosis and 
mast cell depletion in GVHD to t he fibrotic changes in idi-
opathic scleroderma. In the latte r condition, t here have been 
scattered remarks about mast cell degranulation or activation 
[33,34], but no quant itat ive assays were done. We have recently 
carried out a careful quantitative study and found an increased 
number of mast cells in lesional skin (but not in normal skin) 
in patients with scleroderma of less t han 3 years' duration but 
not when the disease was present for over 3 years [35]. We 
believe, t herefo re, that t he mast cell changes are related to t he 
pathogenes is of fibrosis in both chronic GVHD and in sc lero-
derma. 
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